Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective

TL;DR

This paper explores how PSMA-targeted radiopharmaceuticals are improving the diagnosis and treatment of prostate cancer.

Contribution

The paper highlights recent advancements in PSMA-targeted radiopharmaceuticals for prostate cancer.

Findings

PSMA ligands like [68Ga]Ga-PSMA-11 are effective for PET imaging in prostate cancer.

The approval of [177Lu]Lu-PSMA-617 marks a milestone in prostate cancer therapy.

PSMA-targeted radiopharmaceuticals aid in treatment planning and clinical decisions.

Abstract

Prostate-specific membrane antigen (PSMA) has proven to be an important target for diagnostic imaging in prostate cancer. As PSMA is overexpressed on the surface of prostate cancer cells, numerous targeted PSMA ligands have been developed. The emergence of PSMA targeting based on small molecules, such as the PSMA-11 ligand (or PSMA-HBED-CC), has led to breakthroughs, such as [68Ga]Ga-PSMA-11, for positron emission tomography (PET) imaging of biochemically recurrent or metastatic castration-resistant prostate cancer (mCRPC). In addition, the recent approval of [177Lu]Lu-PSMA-617 for the treatment of adult patients with PSMA-positive mCRPC represents an important milestone in prostate cancer therapy. These advances underscore the growing confidence in the use of PSMA-targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer patients. PSMA-targeted radiopharmaceuticals have been shown to significantly impact treatment planning and clinical decision-making and facilitate the customisation of treatment regimens.

Figures